Assess cancer risk, particularly epithelial cell ovarian cancer, in pre- and postmenopausal women who present with an adnexal mass. Not intended as a screening, stand-alone, or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA 125 should be ordered separately.
- Patient Preparation
- Plain red or serum separator tube (SST).
- Specimen Preparation
- Allow specimen to clot completely at room temperature. Transfer 1.5 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Hemolyzed specimens.
- Ambient: 4 hours; Refrigerated: 72 hours; Frozen: 9 months
ROMA is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of having malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18; ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening, stand-alone or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA125 should be ordered separately.
|Component Test Code*||Component Chart Name||LOINC|
|2012621||ROMA Cancer Antigen 125|
|2012622||ROMA Human Epididymis Protein 4|